BEDMINSTER, NJ, USA and DUBLIN, Ireland I April 8, 2013 I Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today additional data from Amarin’s previously announced MARINE and ANCHOR Phase 3 clinical trial results of Vascepa(R) (icosapent ethyl) related to the effect of Vascepa on apolipoprotein C-III (Apo C-III). The lipoprotein Apo C-III is thought to inhibit the clearance of triglycerides from the blood. People who do not produce Apo C-III have lower levels of triglycerides and lower instances of cardiovascular disease.
In Amarin’s MARINE and ANCHOR trials, the 4 gram dose of Vascepa achieved reductions in Apo C-III levels of 25.1% (p
“Amarin is proud of the robust performance of Vascepa in the MARINE and ANCHOR studies,” stated Steven B. Ketchum, Ph.D., President of Research and Development of Amarin. “The Apo C-III data announced today are another example of these positive results.”
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa(R) (icosapent ethyl), Amarin’s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
SOURCE: Amarin
Post Views: 87
BEDMINSTER, NJ, USA and DUBLIN, Ireland I April 8, 2013 I Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today additional data from Amarin’s previously announced MARINE and ANCHOR Phase 3 clinical trial results of Vascepa(R) (icosapent ethyl) related to the effect of Vascepa on apolipoprotein C-III (Apo C-III). The lipoprotein Apo C-III is thought to inhibit the clearance of triglycerides from the blood. People who do not produce Apo C-III have lower levels of triglycerides and lower instances of cardiovascular disease.
In Amarin’s MARINE and ANCHOR trials, the 4 gram dose of Vascepa achieved reductions in Apo C-III levels of 25.1% (p
“Amarin is proud of the robust performance of Vascepa in the MARINE and ANCHOR studies,” stated Steven B. Ketchum, Ph.D., President of Research and Development of Amarin. “The Apo C-III data announced today are another example of these positive results.”
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa(R) (icosapent ethyl), Amarin’s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
SOURCE: Amarin
Post Views: 87
